# EDGAR Filing Document

**Accession Number:** 0001944285
**File Stem:** 0001145549-25-047661
**Filing Date:** 2025-7
**Character Count:** 29233
**Document Hash:** 1dbce27d5cfa9d86ec7d8052b07555a8
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001145549-25-047661.hdr.sgml**: 20250724

**ACCESSION NUMBER**: 0001145549-25-047661

**CONFORMED SUBMISSION TYPE**: NPORT-P

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20250531

**FILED AS OF DATE**: 20250724

**DATE AS OF CHANGE**: 20250724

**PERIOD START**: 20260228

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Tema ETF Trust
- **CENTRAL INDEX KEY:** 0001944285

**ORGANIZATION NAME:**
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** NPORT-P
- **SEC ACT:** 1940 Act
- **SEC FILE NUMBER:** 811-23823
- **FILM NUMBER:** 251147749

**BUSINESS ADDRESS:**
- **STREET 1:** 1919 M STREET, N.W., SUITE 700
- **CITY:** WASHINGTON
- **STATE:** DC
- **ZIP:** 20036
- **BUSINESS PHONE:** 3024994928 EXT. 801

**MAIL ADDRESS:**
- **STREET 1:** 1919 M STREET, N.W., SUITE 700
- **CITY:** WASHINGTON
- **STATE:** DC
- **ZIP:** 20036

## Series and Classes Contracts Data

### Tema Oncology ETF (Series ID: S000078299)

| Class ID   | Class Name        | Ticker Symbol   |
|:---|:---|:---|
| C000239059 | Tema Oncology ETF |  |

## Nport-Ex

---

| | | |
|:---|:---|:---|
| **Tema Oncology ETF** | **Tema Oncology ETF** | **Tema Oncology ETF** |
| **Schedule of Investments** | **Schedule of Investments** | **Schedule of Investments** |
| **May 31, 2025 (Unaudited)** | **May 31, 2025 (Unaudited)** | **May 31, 2025 (Unaudited)** |
| **COMMON STOCKS - 99.6%** | **Shares** | **Value**  |
| **Biotechnology - 67.1%<sup>(a)</sup>** | **Biotechnology - 67.1%<sup>(a)</sup>** | |
| AbbVie, Inc. | 6973 | $1297745 |
| Amgen, Inc. | 6508 | 1875476 |
| AnaptysBio, Inc. <sup>(b)</sup> | 11053 | 245708 |
| Arcellx, Inc. <sup>(b)</sup> | 30040 | 1864282 |
| Arcus Biosciences, Inc. <sup>(b)</sup> | 37110 | 331392 |
| Argenx SE - ADR <sup>(b)</sup> | 1809 | 1037027 |
| Autolus Therapeutics PLC - ADR <sup>(b)</sup> | 116653 | 204143 |
| BeOne Medicines Ltd. - ADR <sup>(b)</sup> | 7473 | 1835219 |
| Blueprint Medicines Corp. <sup>(b)</sup> | 18202 | 1844773 |
| Bridgebio Pharma, Inc. <sup>(b)</sup> | 80180 | 2746165 |
| Celcuity, Inc. <sup>(b)</sup> | 16489 | 175278 |
| CG oncology, Inc. <sup>(b)</sup> | 44659 | 1144164 |
| Cogent Biosciences, Inc. <sup>(b)</sup> | 113994 | 620127 |
| Cullinan Therapeutics, Inc. <sup>(b)</sup> | 41369 | 357635 |
| Day One Biopharmaceuticals, Inc. <sup>(b)</sup> | 105314 | 671903 |
| Exelixis, Inc. <sup>(b)</sup> | 68778 | 2960205 |
| Genmab AS - ADR <sup>(b)</sup> | 116562 | 2441974 |
| Gilead Sciences, Inc. | 7735 | 851469 |
| Ideaya Biosciences, Inc. <sup>(b)</sup> | 67534 | 1343251 |
| Immunocore Holdings PLC - ADR <sup>(b)</sup> | 21522 | 787705 |
| Immunome, Inc. <sup>(b)</sup> | 69992 | 613130 |
| Incyte Corp. <sup>(b)</sup> | 5678 | 369411 |
| Janux Therapeutics, Inc. <sup>(b)</sup> | 48517 | 1154705 |
| Legend Biotech Corp. - ADR <sup>(b)</sup> | 54933 | 1590310 |
| Mereo Biopharma Group PLC - ADR <sup>(b)</sup> | 147616 | 317375 |
| Merus NV <sup>(b)</sup> | 46727 | 2619983 |
| Nurix Therapeutics, Inc. <sup>(b)</sup> | 78601 | 835529 |
| Nuvalent, Inc. - Class A <sup>(b)</sup> | 35699 | 2663502 |
| Regeneron Pharmaceuticals, Inc. | 1459 | 715319 |
| Relay Therapeutics, Inc. <sup>(b)</sup> | 94135 | 282405 |
| Replimune Group, Inc. <sup>(b)</sup> | 39637 | 355940 |
| Revolution Medicines, Inc. <sup>(b)</sup> | 91311 | 3597653 |
| Summit Therapeutics, Inc. <sup>(b)</sup> | 103631 | 1887639 |
| Syndax Pharmaceuticals, Inc. <sup>(b)</sup> | 58434 | 615894 |
| Zai Lab Ltd. - ADR <sup>(b)</sup> | 67877 | 2045813 |
| Zymeworks, Inc. <sup>(b)</sup> | 50253 | 574392 |
|  |  | 44874641 |
| **Health Care Equipment & Supplies - 0.3%** | **Health Care Equipment & Supplies - 0.3%** |  |
| Lantheus Holdings, Inc. <sup>(b)</sup> | 2924 | 220938 |
| **Health Care Providers & Services - 0.7%** | **Health Care Providers & Services - 0.7%** |  |
| Guardant Health, Inc. <sup>(b)</sup> | 10999 | 446779 |
| **Health Care Technology - 0.4%** | **Health Care Technology - 0.4%** |  |
| Schrodinger, Inc. <sup>(b)</sup> | 11892 | 257105 |
| **Life Sciences Tools & Services - 0.5%** | **Life Sciences Tools & Services - 0.5%** |  |
| Illumina, Inc. <sup>(b)</sup> | 3708 | 304946 |
| **Pharmaceuticals - 30.6%<sup>(a)</sup>** | **Pharmaceuticals - 30.6%<sup>(a)</sup>** |  |
| Arvinas, Inc. <sup>(b)</sup> | 38281 | 275623 |
| AstraZeneca PLC | 20437 | 2951827 |
| Bristol-Myers Squibb Co. | 52136 | 2517126 |
| Chugai Pharmaceutical Co. Ltd. | 19954 | 1051539 |
| Daiichi Sankyo Co. Ltd. | 71767 | 1916181 |
| Eli Lilly & Co. | 4188 | 3089362 |
| Enliven Therapeutics, Inc. <sup>(b)</sup> | 31571 | 561017 |
| Merck & Co., Inc. | 22308 | 1714147 |
| Novartis AG | 25507 | 2914244 |
| Roche Holding AG - ADR | 84930 | 3422679 |
|  |  | 20413745 |
| **TOTAL COMMON STOCKS** (Cost $67,744,201) | **TOTAL COMMON STOCKS** (Cost $67,744,201) | 66518154 |
| **SHORT-TERM INVESTMENTS - 0.4%** | **Shares** | **Value**  |
| **Money Market Funds - 0.4%** |  |  |
| First American Treasury Obligations Fund - Class X, 4.23% <sup>(c)</sup> | 294819 | 294819 |
| **TOTAL SHORT-TERM INVESTMENTS** (Cost $294,819) | **TOTAL SHORT-TERM INVESTMENTS** (Cost $294,819) | 294819 |
| **TOTAL INVESTMENTS - 100.0% (**Cost $68,039,020**)** | **TOTAL INVESTMENTS - 100.0% (**Cost $68,039,020**)** | $66812973 |
| Other Assets in Excess of Liabilities - 0.0% <sup>(d)</sup> | Other Assets in Excess of Liabilities - 0.0% <sup>(d)</sup> | 26126 |
| **TOTAL NET ASSETS - 100.0%** |  | $66839099 |
| two | two | –% |
| Percentages are stated as a percent of net assets. | Percentages are stated as a percent of net assets. | –% |
| The Global Industry Classification Standard ("GICS<sup>®</sup>") was developed by and/or is the exclusive property of MSCI, Inc. ("MSCI") and Standard & Poor's Financial Services LLC ("S&P"). GICS<sup>®</sup> is a service mark of MSCI and S&P and has been licensed for use by U.S. Bank Global Fund Services. | The Global Industry Classification Standard ("GICS<sup>®</sup>") was developed by and/or is the exclusive property of MSCI, Inc. ("MSCI") and Standard & Poor's Financial Services LLC ("S&P"). GICS<sup>®</sup> is a service mark of MSCI and S&P and has been licensed for use by U.S. Bank Global Fund Services. | The Global Industry Classification Standard ("GICS<sup>®</sup>") was developed by and/or is the exclusive property of MSCI, Inc. ("MSCI") and Standard & Poor's Financial Services LLC ("S&P"). GICS<sup>®</sup> is a service mark of MSCI and S&P and has been licensed for use by U.S. Bank Global Fund Services. |

---

ADR - American Depositary Receipt <br> PLC - Public Limited Company

(a) To the extent that the Fund invests more heavily in a particular industry or sector of the economy, its performance will be especially sensitive to developments that significantly affect those
 industries or sectors.

(b) Non-income producing security.

(c) The rate shown represents the 7-day annualized effective yield as of May 31, 2025.

(d) Represents less than 0.05% of net assets.

------

#### Tema ETF Trust

#### Tema Oncology ETF
Notes to Quarterly Schedule of Investments

May 31, 2025 (Unaudited)

#### Investment Valuation
The Fund discloses the fair value of their investments in a hierarchy that distinguishes between: (1) market participant assumptions developed based on market data obtained from sources independent of the Fund's (observable inputs) and (2) the Fund's own assumptions about market participant assumptions developed based on the best information available under the circumstances (unobservable inputs). The three levels defined by the hierarchy are as follows:

**• Level 1** — Quoted prices in active markets for identical assets that the Fund's have the ability to access.

**• Level 2** — Other significant observable inputs (including quoted prices for similar securities, interest rates, prepayment speeds, credit risk, etc.).

**• Level 3** — Significant unobservable inputs (including the Fund's own assumptions in determining the fair value of investments).

The inputs or methodology used for valuing securities are not necessarily an indication of the risk associated with investing in those securities.

The following is a summary of the inputs used to value the Fund's investments as of May 31, 2025:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **<u>Level 1</u>** | **<u>Level 2</u>** | **<u>Level 3</u>** | **<u>Total</u>** |
| <u>Investments:</u> |  |  |  |  |
|  &nbsp;&nbsp;&nbsp;&nbsp;Common Stocks | $66518154 | $– | $– | $66518154 |
|  &nbsp;&nbsp;&nbsp;&nbsp;Money Market Funds | 294819 | – | – | 294819 |
| Total Investments | $66812973 | $– | $– | $66812973 |
| Refer to the Schedule of Investments for further disaggregation of investment categories. | Refer to the Schedule of Investments for further disaggregation of investment categories. | Refer to the Schedule of Investments for further disaggregation of investment categories. | Refer to the Schedule of Investments for further disaggregation of investment categories. | Refer to the Schedule of Investments for further disaggregation of investment categories. |

---

---

| | | |
|:---|:---|:---|
| **Allocation of Portfolio Holdings by Country as of May 31, 2025** | **Allocation of Portfolio Holdings by Country as of May 31, 2025** | |
| (% of Net Assets) | (% of Net Assets) |  |
| United States | $45102483 | 67.4% |
| Switzerland | 6336923 | 9.5 |
| United Kingdom | 4261050 | 6.4 |
| Netherlands | 3657010 | 5.4 |
| Japan | 2967720 | 4.5 |
| Denmark | 2441974 | 3.7 |
| China | 2045813 | 3.1 |
| Other Assets in Excess of Liabilities | 26126 | 0.0<br> <sup>(a)</sup>  |
|  | $**66839099** | 100.0<br> **%** |

---

(a) Represents less than 0.05% of net assets.

---

| | | |
|:---|:---|:---|
| **Sector Classification as of May 31, 2025** | **Sector Classification as of May 31, 2025** | |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (% of Net Assets) |  |  |
| Health Care | $66518154 | 99.6% |
| Money Market Funds | 294819 | 0.4 |
| Other Assets in Excess of Liabilities | 26126 | 0.0<br> <sup>(a)</sup>  |
|  | **66839099** | 100.0<br> **%** |

---

(a) Represents less than 0.05% of net assets.

## Form NPORT-P: Monthly Portfolio Investments Report

### NPORT-P: Part A: General Information

**Item A.1. Information about the Registrant.**

- **a. Name of Registrant:** Tema ETF Trust

- **b. Investment Company Act file number:** 811-23823

- **c. CIK number of Registrant:** 0001944285

- **d. LEI of Registrant:** 549300JKGDXNE2CLUY37

- **e. Address and telephone number of Registrant.**

  - **Street Address 1:** 200 Vesey Street

  - **City:** New York

  - **State:** NY

  - **Foreign country:** US

  - **Zip / Postal Code:** 10281

  - **Telephone number:** 3024994928 EXT 801

**Item A.2. Information about the Series.**

- **a. Name of Series:** Tema Oncology ETF

- **b. EDGAR series identifier (if any):** S000078299

- **c. LEI of Series:** 549300N3IU4YD19QLF24

**Item A.3. Reporting period.**

- **a. Date of fiscal year-end:** 2026-02-28

- **b. Date as of which information is reported:** 2025-05-31

**Item A.4. Final filing**

Does the Fund anticipate that this will be its final filing on Form N-PORT? **No**

### Fund Information

**Total Assets:** $66882155.15

**Total Liabilities:** $43055.99

**Net Assets:** $66839099.16

**Monthly Return Information**

| Class               | Month 1 Return (%)   | Month 2 Return (%)   | Month 3 Return (%)   |
|:---|:---|:---|:---|
| Class ID C000239059 | -6.19%               | 4.09%                | -4.86%               |

**Monthly Gains & Losses**

| Period   | Net Realized Gain/Loss   | Net Unrealized Appreciation/Depreciation   |
|:---|:---|:---|
| Month 1  | $39864.22                | $-4415610.16                               |
| Month 2  | $46002.27                | $2687531.62                                |
| Month 3  | $-345313.78              | $-2946598.42                               |

**Designated Index Information**

- **Index Name:** N/A

- **Index Identifier:** N/A

### Schedule of Portfolio Investments

| Name                           | Title                                    | Identifiers                                   | Payoff Profile   | Asset Category   | Issuer Category   | Country   |   Balance | Units   | Value (USD)   | % of Net Assets   | Maturity Date   | Coupon Type   | Annualized Rate (%)   | Restricted?   |   Fair Value Level | Lending Status   |
|:---|:---|:---|:---|:---|:---|:---|---:|:---|:---|:---|:---|:---|:---|:---|---:|:---|
| Janux Therapeutics Inc         | Janux Therapeutics Inc                   | CUSIP: 47103J105<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     48517 | NS      | $1154704.60   | 1.73%             |  |  |  | No            |                  1 | On Loan: No      |
| Lantheus Holdings Inc          | Lantheus Holdings Inc                    | CUSIP: 516544103<br>LEI: 5299005HUB5IOJGO7S39 | Long             | EC               | CORP              | US        |      2924 | NS      | $220937.44    | 0.33%             |  |  |  | No            |                  1 | On Loan: No      |
| Mereo Biopharma Group PLC      | Mereo Biopharma Group PLC                | CUSIP: 589492107<br>LEI: 213800U8JQHIJOS5AS09 | Long             | EC               | CORP              | GB        |    147616 | NS      | $317374.40    | 0.47%             |  |  |  | No            |                  1 | On Loan: No      |
| Nurix Therapeutics Inc         | Nurix Therapeutics Inc                   | CUSIP: 67080M103<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     78601 | NS      | $835528.63    | 1.25%             |  |  |  | No            |                  1 | On Loan: No      |
| Immunocore Holdings PLC        | Immunocore Holdings PLC                  | CUSIP: 45258D105<br>LEI: 213800IUE3DFS84BVN18 | Long             | EC               | CORP              | GB        |     21522 | NS      | $787705.20    | 1.18%             |  |  |  | No            |                  1 | On Loan: No      |
| Novartis AG                    | Novartis AG                              | CUSIP: N/A<br>LEI: 5493007HIVTX6SY6XD66       | Long             | EC               | CORP              | CH        |     25507 | NS      | $2914244.48   | 4.36%             |  |  |  | No            |                  1 | On Loan: No      |
| AbbVie Inc                     | AbbVie Inc                               | CUSIP: 00287Y109<br>LEI: FR5LCKFTG8054YNNRU85 | Long             | EC               | CORP              | US        |      6973 | NS      | $1297745.03   | 1.94%             |  |  |  | No            |                  1 | On Loan: No      |
| Autolus Therapeutics PLC       | Autolus Therapeutics PLC                 | CUSIP: 05280R100<br>LEI: 549300C0KZP8EYROLL02 | Long             | EC               | CORP              | GB        |    116653 | NS      | $204142.75    | 0.31%             |  |  |  | No            |                  1 | On Loan: No      |
| Cogent Biosciences Inc         | Cogent Biosciences Inc                   | CUSIP: 19240Q201<br>LEI: N/A                  | Long             | EC               | CORP              | US        |    113994 | NS      | $620127.36    | 0.93%             |  |  |  | No            |                  1 | On Loan: No      |
| Genmab A/S                     | Genmab A/S                               | CUSIP: 372303206<br>LEI: 529900MTJPDPE4MHJ122 | Long             | EC               | CORP              | DK        |    116562 | NS      | $2441973.90   | 3.65%             |  |  |  | No            |                  1 | On Loan: No      |
| Ideaya Biosciences Inc         | Ideaya Biosciences Inc                   | CUSIP: 45166A102<br>LEI: 549300ULW08F62IJML11 | Long             | EC               | CORP              | US        |     67534 | NS      | $1343251.26   | 2.01%             |  |  |  | No            |                  1 | On Loan: No      |
| Nuvalent Inc                   | Nuvalent Inc                             | CUSIP: 670703107<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     35699 | NS      | $2663502.39   | 3.98%             |  |  |  | No            |                  1 | On Loan: No      |
| Summit Therapeutics Inc        | Summit Therapeutics Inc                  | CUSIP: 86627T108<br>LEI: N/A                  | Long             | EC               | CORP              | US        |    103631 | NS      | $1887638.67   | 2.82%             |  |  |  | No            |                  1 | On Loan: No      |
| Arcellx Inc                    | Arcellx Inc                              | CUSIP: 03940C100<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     30040 | NS      | $1864282.40   | 2.79%             |  |  |  | No            |                  1 | On Loan: No      |
| First American Treasury Obliga | First American Treasury Obligations Fund | CUSIP: 31846V328<br>LEI: 549300UU586IAH2B8H03 | Long             | STIV             | RF                | US        |    294819 | NS      | $294818.98    | 0.44%             |  |  |  | No            |                  1 | On Loan: No      |
| Guardant Health Inc            | Guardant Health Inc                      | CUSIP: 40131M109<br>LEI: 254900M8C3E5VC8BR186 | Long             | EC               | CORP              | US        |     10999 | NS      | $446779.38    | 0.67%             |  |  |  | No            |                  1 | On Loan: No      |
| Illumina Inc                   | Illumina Inc                             | CUSIP: 452327109<br>LEI: SQ95QG8SR5Q56LSNF682 | Long             | EC               | CORP              | US        |      3708 | NS      | $304945.92    | 0.46%             |  |  |  | No            |                  1 | On Loan: No      |
| Roche Holding AG               | Roche Holding AG                         | CUSIP: 771195104<br>LEI: 549300U41AUUVOAAOB37 | Long             | EC               | CORP              | CH        |     84930 | NS      | $3422679.00   | 5.12%             |  |  |  | No            |                  1 | On Loan: No      |
| Schrodinger Inc/United States  | Schrodinger Inc/United States            | CUSIP: 80810D103<br>LEI: 984500044BAE4791E559 | Long             | EC               | CORP              | US        |     11892 | NS      | $257105.04    | 0.38%             |  |  |  | No            |                  1 | On Loan: No      |
| Daiichi Sankyo Co Ltd          | Daiichi Sankyo Co Ltd                    | CUSIP: N/A<br>LEI: 353800XGIU2IHQGC9504       | Long             | EC               | CORP              | JP        |     71767 | NS      | $1916180.65   | 2.87%             |  |  |  | No            |                  1 | On Loan: No      |
| Blueprint Medicines Corp       | Blueprint Medicines Corp                 | CUSIP: 09627Y109<br>LEI: 5299004CC60O9T5HVM83 | Long             | EC               | CORP              | US        |     18202 | NS      | $1844772.70   | 2.76%             |  |  |  | No            |                  1 | On Loan: No      |
| Exelixis Inc                   | Exelixis Inc                             | CUSIP: 30161Q104<br>LEI: 254900PJQB59O2O95R37 | Long             | EC               | CORP              | US        |     68778 | NS      | $2960205.12   | 4.43%             |  |  |  | No            |                  1 | On Loan: No      |
| Bristol-Myers Squibb Co        | Bristol-Myers Squibb Co                  | CUSIP: 110122108<br>LEI: HLYYNH7UQUORYSJQCN42 | Long             | EC               | CORP              | US        |     52136 | NS      | $2517126.08   | 3.77%             |  |  |  | No            |                  1 | On Loan: No      |
| CG oncology Inc                | CG oncology Inc                          | CUSIP: 156944100<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     44659 | NS      | $1144163.58   | 1.71%             |  |  |  | No            |                  1 | On Loan: No      |
| Amgen Inc                      | Amgen Inc                                | CUSIP: 031162100<br>LEI: 62QBXGPJ34PQ72Z12S66 | Long             | EC               | CORP              | US        |      6508 | NS      | $1875475.44   | 2.81%             |  |  |  | No            |                  1 | On Loan: No      |
| Arcus Biosciences Inc          | Arcus Biosciences Inc                    | CUSIP: 03969F109<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     37110 | NS      | $331392.30    | 0.50%             |  |  |  | No            |                  1 | On Loan: No      |
| Argenx SE                      | Argenx SE                                | CUSIP: 04016X101<br>LEI: 7245009C5FZE6G9ODQ71 | Long             | EC               | CORP              | NL        |      1809 | NS      | $1037027.34   | 1.55%             |  |  |  | No            |                  1 | On Loan: No      |
| BeOne Medicines Ltd            | BeOne Medicines Ltd                      | CUSIP: 07725L102<br>LEI: 549300JFUK6FRD5MH739 | Long             | EC               | CORP              | US        |      7473 | NS      | $1835219.34   | 2.75%             |  |  |  | No            |                  1 | On Loan: No      |
| Bridgebio Pharma Inc           | Bridgebio Pharma Inc                     | CUSIP: 10806X102<br>LEI: 54930028YG89VTY2J114 | Long             | EC               | CORP              | US        |     80180 | NS      | $2746165.00   | 4.11%             |  |  |  | No            |                  1 | On Loan: No      |
| Enliven Therapeutics Inc       | Enliven Therapeutics Inc                 | CUSIP: 29337E102<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     31571 | NS      | $561016.67    | 0.84%             |  |  |  | No            |                  1 | On Loan: No      |
| Gilead Sciences Inc            | Gilead Sciences Inc                      | CUSIP: 375558103<br>LEI: 549300WTZWR07K8MNV44 | Long             | EC               | CORP              | US        |      7735 | NS      | $851468.80    | 1.27%             |  |  |  | No            |                  1 | On Loan: No      |
| Immunome Inc                   | Immunome Inc                             | CUSIP: 45257U108<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     69992 | NS      | $613129.92    | 0.92%             |  |  |  | No            |                  1 | On Loan: No      |
| Legend Biotech Corp            | Legend Biotech Corp                      | CUSIP: 52490G102<br>LEI: 254900EIUFZTW136H859 | Long             | EC               | CORP              | US        |     54933 | NS      | $1590310.35   | 2.38%             |  |  |  | No            |                  1 | On Loan: No      |
| Eli Lilly & Co                 | Eli Lilly & Co                           | CUSIP: 532457108<br>LEI: FRDRIPF3EKNDJ2CQJL29 | Long             | EC               | CORP              | US        |      4188 | NS      | $3089361.96   | 4.62%             |  |  |  | No            |                  1 | On Loan: No      |
| Merck & Co Inc                 | Merck & Co Inc                           | CUSIP: 58933Y105<br>LEI: 4YV9Y5M8S0BRK1RP0397 | Long             | EC               | CORP              | US        |     22308 | NS      | $1714146.72   | 2.56%             |  |  |  | No            |                  1 | On Loan: No      |
| Chugai Pharmaceutical Co Ltd   | Chugai Pharmaceutical Co Ltd             | CUSIP: N/A<br>LEI: 529900T9LAII161DCN95       | Long             | EC               | CORP              | JP        |     19954 | NS      | $1051538.84   | 1.57%             |  |  |  | No            |                  1 | On Loan: No      |
| Regeneron Pharmaceuticals Inc  | Regeneron Pharmaceuticals Inc            | CUSIP: 75886F107<br>LEI: 549300RCBFWIRX3HYQ56 | Long             | EC               | CORP              | US        |      1459 | NS      | $715318.52    | 1.07%             |  |  |  | No            |                  1 | On Loan: No      |
| Relay Therapeutics Inc         | Relay Therapeutics Inc                   | CUSIP: 75943R102<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     94135 | NS      | $282405.00    | 0.42%             |  |  |  | No            |                  1 | On Loan: No      |
| Replimune Group Inc            | Replimune Group Inc                      | CUSIP: 76029N106<br>LEI: 549300AY704NEIRC4K64 | Long             | EC               | CORP              | US        |     39637 | NS      | $355940.26    | 0.53%             |  |  |  | No            |                  1 | On Loan: No      |
| Revolution Medicines Inc       | Revolution Medicines Inc                 | CUSIP: 76155X100<br>LEI: 549300JU3X0LBCQ65892 | Long             | EC               | CORP              | US        |     91311 | NS      | $3597653.40   | 5.38%             |  |  |  | No            |                  1 | On Loan: No      |
| Zymeworks Inc                  | Zymeworks Inc                            | CUSIP: 98985Y108<br>LEI: 894500AHOYAGYLYZJL67 | Long             | EC               | CORP              | US        |     50253 | NS      | $574391.79    | 0.86%             |  |  |  | No            |                  1 | On Loan: No      |
| Merus NV                       | Merus NV                                 | CUSIP: N/A<br>LEI: 549300W8GPUWU8QNU293       | Long             | EC               | CORP              | NL        |     46727 | NS      | $2619982.89   | 3.92%             |  |  |  | No            |                  1 | On Loan: No      |
| AnaptysBio Inc                 | AnaptysBio Inc                           | CUSIP: 032724106<br>LEI: 529900HH4WQT03IG1A12 | Long             | EC               | CORP              | US        |     11053 | NS      | $245708.19    | 0.37%             |  |  |  | No            |                  1 | On Loan: No      |
| Day One Biopharmaceuticals Inc | Day One Biopharmaceuticals Inc           | CUSIP: 23954D109<br>LEI: N/A                  | Long             | EC               | CORP              | US        |    105314 | NS      | $671903.32    | 1.01%             |  |  |  | No            |                  1 | On Loan: No      |
| Arvinas Inc                    | Arvinas Inc                              | CUSIP: 04335A105<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     38281 | NS      | $275623.20    | 0.41%             |  |  |  | No            |                  1 | On Loan: No      |
| AstraZeneca PLC                | AstraZeneca PLC                          | CUSIP: N/A<br>LEI: PY6ZZQWO2IZFZC3IOL08       | Long             | EC               | CORP              | GB        |     20437 | NS      | $2951827.54   | 4.42%             |  |  |  | No            |                  1 | On Loan: No      |
| Cullinan Therapeutics Inc      | Cullinan Therapeutics Inc                | CUSIP: 230031106<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     41369 | NS      | $357635.01    | 0.54%             |  |  |  | No            |                  1 | On Loan: No      |
| Celcuity Inc                   | Celcuity Inc                             | CUSIP: 15102K100<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     16489 | NS      | $175278.07    | 0.26%             |  |  |  | No            |                  1 | On Loan: No      |
| Incyte Corp                    | Incyte Corp                              | CUSIP: 45337C102<br>LEI: 549300Z4WN6JVZ3T4680 | Long             | EC               | CORP              | US        |      5678 | NS      | $369410.68    | 0.55%             |  |  |  | No            |                  1 | On Loan: No      |
| Syndax Pharmaceuticals Inc     | Syndax Pharmaceuticals Inc               | CUSIP: 87164F105<br>LEI: 529900OF94TRHKZVBS87 | Long             | EC               | CORP              | US        |     58434 | NS      | $615894.36    | 0.92%             |  |  |  | No            |                  1 | On Loan: No      |
| Zai Lab Ltd                    | Zai Lab Ltd                              | CUSIP: 98887Q104<br>LEI: 549300P2UYQ9U5LY1T58 | Long             | EC               | CORP              | CN        |     67877 | NS      | $2045812.78   | 3.06%             |  |  |  | No            |                  1 | On Loan: No      |

### Signature

**Date Signed:** 2025-07-23

**Name of Applicant:** Tema ETF Trust

**Signature:** /s/ Josh Hunter

**Name of Signer:** Josh Hunter

**Title:** Treasurer